Cover -- Copyright Page -- Contents -- Contributors to Volume 82 -- Chapter 1. Retinoblastoma Protein Partners -- I. An Introduction to pRb-Binding Proteins -- II. Potential pRb Partners -- References -- Chapter 2. p53-Dependent Apoptosis Pathways -- I. p53 -- II. Bcl-2 Family -- III. Caspase Family -- IV. IAPs -- V. p53-Mediated Apoptosis in Cancer Therapy -- References -- Chapter 3. von Hippel-Lindau Disease: Clinical and Molecular Perspectives -- I. The VHL Gene and VHL Disease -- II. The VHL TSG and Sporadic Cancers -- III. Functional Analysis of The VHL Tumor Suppressor Gene -- IV. Conclusion -- References -- Chapter 4. Nitric Oxide-Induced Apoptosis in Tumor Cells -- I. Introduction -- II. NO and Antimetastatic Resistance -- III. Mechanisms of NO-Mediated Apoptosis -- IV. Concluding Remarks -- References -- Chapter 5. Detection of Minimal Residual Disease -- I. Introduction -- II. Technical Aspects of the Detection of Minimal Residual Disease -- III. MRD in Leukemia -- IV. MRD in Lymphoma -- V. MRD in Solid Tumors -- VI. Concluding Remarks -- References -- Chapter 6. Modeling Prostate Cancer in the Mouse -- I. Introduction -- II. Anatomy of the Adult Prostate Gland -- III. Embryology and Growth of the Prostate Gland -- IV. Components of the Epithelial Compartment: Do Prostate Stem Cells Exist? -- V. Role of Oncogenes and Tumor Suppressors in Prostate Neoplasia -- VI. Progress in the Development of CaP Animal Models -- References -- Chapter 7. Immunity to Oncogenic Human Papillomaviruses -- I. Epidemiology of Human Papillomavirus Infection -- II. The Antibody Response to HPV Infection -- III. Cellular Immunity to HPV Infection -- IV. Does Cross-Protective Immunity Exist? -- References -- Index -- Last Page.
0
SUMMARY OR ABSTRACT
Text of Note
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including nitric oxide-induced apoptosis in tumor cells, detection of minimal residual disease, immunity to oncogenetic human papilloma viruses, and modeling prostate cancer in the mouse.